Risperidone in the treatment of first-episode psychotic patients: A double-blind multicenter study

Schizophrenia Bulletin

Volumn 25, Issue 4, 1999, Pages 721-729

  Emsley, R A ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

First episode psychosis; Haloperidol; Risperidone

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MENTAL DISEASE; MULTICENTER STUDY; PARKINSONISM; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0033372843     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a033413     Document Type: Article

References (23)

1. American Psychiatric Association. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders. 3rd ed., revised. Washington, DC: The Association, 1987.
2. Andreasen, N.C. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: The University of Iowa, 1983.
3. Carman, J.; Peuskens, J.; and Vangeneugden, A. Risperidone in the treatment of negative symptoms of schizophrenia: A meta-analysis. International Clinical Psychopharmacology, 10:207-213, 1995.
4. Chakos, M.H.; Lieberman, J.A.; Bilder, R.M.; Borenstein, M.; Lerner, G.; Bogerts, B.; Wu, H.; Kinon, B.; and Ashtari, M. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. American Journal of Psychiatry, 151:1430-1436, 1994.
5. Chakos, M.H.; Mayerhoff, D.I.; Loebel, A.D.; Alvir, J.M.J.; and Lieberman, J.A. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacology Bulletin, 28:81-86, 1992.
6. Chouinard, G.; Jones, B.; Remington, G.; Bloom, D.; Addington, D.; MacEwan, G.W.; Labelle, A.; Beauclair, L.; and Arnott, W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 13:25-40, 1993.
7. Chouinard, G.; Ross-Chouinard, A.; Annable, L.; and Jones, B.D. Extrapyramidal Symptom Rating Scale. Canadian Journal of Neurological Sciences, 7:233, 1980.
8. Endicott, J., and Spitzer, R.L. A diagnostic interview: The Schedule for Affective Disorders and Schizophrenia. Archives of General Psychiatry, 35:837-844, 1978.
9. Guy, W., ed. ECDEU Assessment Manual for Psychopharmacology. Publication ADM 76-338. Washington, DC: U.S. Department of Health, Education, and Welfare, 1976.
10. Kay, S.R.; Fiszbein, A.; and Opler, L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13:261-267, 1987.
11. Keshavan, M.S.; Bagwell, W.W.; Haas, G.L.; Sweeney, J.A.; Schooler, N.R.; and Pettegrew, J.W. Changes in caudate volume with neuroleptic treatment. Lancet 344:1434, 1994.
12. Kopala, L.C.; Fredrikson, D.; Good, K.P.; and Honer, W.G. Symptoms in neuroleptic-naive, first-episode schizophrenia: Response to risperidone. Biological Psychiatry, 39:296-298, 1996.
13. Kopala, L.C.; Good, K.P; and Honer, W.G. Extra-pyramidal signs and clinical symptoms in first-episode schizophrenia: Response to low-dose risperidone. Journal of Clinical Psychopharmacology, 17:308-313, 1997.
14. Krawiecka, M.; Goldberg, D.; and Vaughan, M. A standardized psychiatric assessment scale for rating psychotic patients. Acta Psychiatrica Scandinavica, 55:299-308, 1977.
15. Lieberman, J.; Jody, D.; Geisler, S.; Vital-Herne, J.; Alvir, J.M.J.; Walsleben, J.; and Woerner, M.G. Treatment outcome of first-episode schizophrenic patients. Psychopharmacology Bulletin, 25:92-96, 1989.
16. Marder, S.R., and Meibach, R.C. Risperidone in the treatment of chronic schizophrenia. American Journal of Psychiatry, 151:825-835, 1994.
17. McEvoy, J.P.; Hogarty, G.E.; and Steingard, S. Optimal dose of neuroleptic in acute schizophrenia: A controlled study of the neuroleptic threshold and higher haloperidol doses. A rchives of General Psychiatry, 48:739-744, 1991.
18. Möller, H.-J.; Müller, H.; Borison, R.L.; Schooler, N.R.; and Chouinard, G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: A re-evaluation of the North American risperidone study. European Archives of Psychiatry and Clinical Neuroscience, 245:45-49, 1995.
19. Overall, J.E., and Gorham, D.R. The Brief Psychiatric Rating Scale. Psychological Reports, 10:799-812, 1962.
20. Peuskens, J. Risperidone in the treatment of chronic schizophrenic patients: A multinational, multicentre, double-blind, parallel-group study versus haloperidol. British Journal of Psychiatry, 166:712-726, 1995.
21. ™ (Risperidone) package insert. Titusville, NJ: Janssen Pharmaceutica, 1996.
22. Scottish Schizophrenia Research Group. The Scottish first episode schizophrenia study. II. Treatment: Pimozide versus flupentixol. British Journal of Psychiatry, 150:334-338, 1987.
23. Syzmanski, S.R.; Cannon, T.D.; Gallacher, F.; Erwin, R.J.; and Gur, R.E. Course of treatment response in first-episode and chronic schizophrenia. American Journal of Psychiatry, 153:519-525, 1996.